PTJ
BLCM

Paul Tudor Jones’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Paul Tudor Jones’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,115
Closed -$73K – 1281
2018
Q1 		$73K Buy
+1,115
New +$84.2K ﹤0.01% 936
2017
Q3 		– Sell
-1,302
Closed -$152K – 1299
2017
Q2 		$152K Sell
1,302
-5,504
-81% -$683K ﹤0.01% 925
2017
Q1 		$840K Buy
+6,806
New +$892K 0.03% 458
2015
Q1 		– Sell
-1,000
Closed -$230K – 1662
2014
Q4 		$230K Buy
+1,000
New +$214K 0.01% 1204

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paul Tudor Jones's BLCM Position: Q2 2018 in Review

Paul Tudor Jones sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2018, closing a stake of 1,115 shares — an estimated $73K sold.

Paul Tudor Jones first reported a position in BLCM in Q4 2014 and held it in 4 quarters. The position peaked at $840K in Q1 2017. 96 funds tracked by Wall St. Rank hold BLCM as of Q2 2018.

  • Paul Tudor Jones reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Paul Tudor Jones sold 1,115 Bellicum Pharmaceuticals, Inc. shares in Q2 2018, an estimated $73K.
  • Paul Tudor Jones first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 4 quarters.
  • Paul Tudor Jones's Bellicum Pharmaceuticals, Inc. position peaked at $840K in Q1 2017.
  • 96 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2018.

Based on Tudor Investment Corp's 13F filing for Q2 2018, filed 14 Aug 2018.